New antibody treatment aims to protect transplanted kidneys from common virus
NCT ID NCT05769582
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an antibody drug called AntiBKV in 95 kidney transplant patients with BK virus infection. The virus can damage the new kidney if not controlled. Patients received four doses of the drug or a placebo over four months. The goal was to see if the drug could clear the virus from the blood and prevent kidney injury.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AntiBKV (an antibody drug given by IV infusion)
What this could lead to
If it works, this could offer a new treatment to control BK virus in kidney transplant patients, reducing the risk of kidney damage and graft loss.
What could go wrong
This is an early-to-mid stage trial with only 95 participants. The drug may not clear the virus effectively, and side effects from the infusion or immune reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BK VIREMIA; BKV DNAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Hartford Hospital
Hartford, Connecticut, 06105, United States
-
Harvard Medical School
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Transplant Center
Jacksonville, Florida, 32224, United States
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Metrolina Nephrology Associates (MNA), PA
Charlotte, North Carolina, 28207, United States
-
New York Presbyterian Hospital - Weill Cornell Medical Center
New York, New York, 10065, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Saint Barnabas Medical Center
Livingston, New Jersey, 07039, United States
-
UT Southwestern
Dallas, Texas, 75390, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of California Davis
Sacramento, California, 95817, United States
-
University of California, Los Angeles
Los Angeles, California, 90024, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
-
University of Pennsylvania Hospital of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Washington Medical Center
Seattle, Washington, 98195, United States
-
Washington University School of Medicine in St. Louis
St Louis, Missouri, 63110, United States
-
Yale University School of Medicine
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.